mis17 Antibody

What is the IL-17 family and why are antibodies against these cytokines important in research?

The IL-17 family consists of structurally similar cytokines that play crucial roles in inflammatory processes. IL-17A and IL-17F are particularly significant members that have been implicated in immune-mediated inflammatory diseases including psoriasis, psoriatic arthritis, and axial spondyloarthritis . Antibodies targeting these cytokines are important research tools for understanding inflammatory pathways and have emerged as therapeutic agents. IL-17A is considered a key driver of inflammation and has become the principal target of anti-IL-17 therapeutic monoclonal antibodies . These antibodies allow researchers to neutralize specific cytokines in experimental systems to understand their individual contributions to disease processes.

What is the Rh17 antigen and associated antibodies?

Rh17, also called Hr0, is a high-frequency antigen in the Rhesus blood group system with a prevalence of nearly 100% in the general population. The Rh17 antigen comprises several epitopes on the RhCE protein . Anti-Rh17 antibodies can be produced by individuals with missing or varied C/c, E/e antigens, including phenotypes such as D--, D.., Dc-, and DCw- . These antibodies are clinically significant in the context of hemolytic disease of the fetus and newborn (HDFN) and can present significant challenges in transfusion medicine due to the extreme rarity of compatible blood (fewer than 1 in 100,000 people are classified as Rh17 negative) .

How are antibody specificities against IL-17 family members experimentally validated?

Validating antibody specificity against IL-17 family members involves several experimental approaches. One method is to assess the ability of antibodies to block IL-17-dependent signaling in specialized cell lines, such as the murine stromal cell line ST2 . In such assays, cells are treated with specific IL-17 cytokines (IL-17A, IL-17F, or IL-17AF heterodimers) alone or in combination with other cytokines like TNF-α, which signals synergistically with IL-17. The production of downstream inflammatory mediators, such as IL-6, serves as a readout for IL-17 activity .

For example, in one study, anti-IL-17A antibodies efficiently blocked IL-6 production in ST2 cells treated with IL-17A ± TNF-α but not IL-17F ± TNF-α. These antibodies also blocked IL-17AF activity, confirming their ability to neutralize both IL-17A and IL-17AF heterodimers. Conversely, anti-IL-17F antibodies only neutralized IL-17F without affecting IL-17A or IL-17AF signaling . These functional assays are crucial for determining the precise specificity profiles of antibodies targeting IL-17 family members.

What methodological approaches are used to study the role of IL-17 antibodies in fungal immunity?

Studying the role of IL-17 antibodies in fungal immunity typically employs a combination of genetic knockout models and antibody neutralization studies. The mouse model of acute oropharyngeal candidiasis (OPC) has been particularly valuable in this context . In this model, wild-type mice are administered antibodies against specific IL-17 family members prior to and during infection with Candida albicans.

The protocol typically involves:

• Administration of antibodies intraperitoneally (e.g., 100–500 μg/injection) on days -1, +1, and +2 relative to infection

• Oral infection with C. albicans

• Assessment of fungal burden in oral tissues several days post-infection

• Comparison of results with control mice receiving isotype-matched antibodies

This approach allows researchers to determine the specific contributions of individual IL-17 family members to antifungal immunity. Additionally, studies often include genetic knockout mice (e.g., IL-17A−/−, IL-17F−/−) for comparison with antibody-mediated neutralization . The combined use of genetic and antibody-based approaches provides complementary insights into the roles of these cytokines in host defense.

What are the principles behind computational design of antibodies with customized specificity profiles?

Recent advances have enabled the computational design of antibodies with highly specific binding profiles, particularly for discriminating between very similar ligands like IL-17 family members. This approach combines high-throughput sequencing data from phage display experiments with downstream computational analysis .

The process involves:

• Identification of different binding modes associated with particular ligands

• Development of biophysics-informed models that can disentangle these modes, even for chemically similar ligands

• Optimization of energy functions associated with each binding mode

• Generation of novel antibody sequences with predefined binding profiles

For cross-specific antibodies (binding to multiple ligands), researchers jointly minimize the energy functions associated with the desired ligands. For highly specific antibodies, they minimize the energy function for the desired ligand while maximizing the energy functions for undesired ligands . This computational approach extends beyond what can be achieved through experimental selection alone, allowing researchers to design antibodies with custom specificity profiles not directly represented in the training data.

How has affinity maturation been employed to develop dual-targeting antibodies against IL-17A and IL-17F?

The development of bimekizumab, a humanized IgG1 antibody that neutralizes both IL-17A and IL-17F, showcases a sophisticated approach to affinity maturation. The initial antibody, 496.g1, had strong affinity for IL-17A but poor affinity for IL-17F . Through targeted affinity maturation, researchers enhanced the binding to IL-17F while maintaining strong affinity for IL-17A.

The process involved:

• Application of in silico design methods to the binding interface

• Testing a series of mutation combinations

• Identification of five critical mutations in the light chain variable region that increased binding affinity for IL-17F while also improving affinity for IL-17A

These modifications transformed the original antibody into 496.g3 (later named bimekizumab), which as a purified Fab fragment demonstrated affinity constants (KD) of 35 pM for IL-17F and 7 pM for IL-17A . As a complete IgG1, the affinity for IL-17A and IL-17F was further enhanced to 3.2 pM and 23 pM, respectively . This dual-targeting capability distinguishes bimekizumab from commercially available anti-IL-17A monoclonal antibodies like ixekizumab and secukinumab, which primarily neutralize IL-17A.

What challenges arise in studying and applying rare antibodies like anti-Rh17?

Studying and applying rare antibodies like anti-Rh17 presents several significant challenges for researchers:

• Extremely limited availability of compatible blood samples: With fewer than 1 in 100,000 people being Rh17 negative, obtaining appropriate samples for research is exceptionally difficult. In clinical situations, even specialized programs like the American Rare Donor Program may be unable to locate suitable blood units .

• Complex phenotyping requirements: Accurate identification of Rh17-negative samples requires comprehensive serological testing and potentially molecular analysis of the RHD and RHCE genes, which encode the proteins carrying Rh antigens. These genes are highly homologous and located closely on chromosome 1 (1p36.11) .

• Clinical urgency competing with research needs: When anti-Rh17 antibodies are identified in patients requiring transfusion, the clinical emergency often takes precedence over research considerations. This limits opportunities for systematic investigation.

• Transnational coordination challenges: Given the rarity of Rh17-negative individuals, international collaboration is often necessary to locate compatible donors. This introduces logistical complexities for both clinical applications and research studies.

What cell-based assays are used to evaluate the functional activity of anti-IL-17 antibodies?

Researchers employ several cell-based assays to evaluate the functional activity of anti-IL-17 antibodies. A commonly used approach involves stimulating cells that express IL-17 receptors with recombinant IL-17 cytokines in the presence or absence of neutralizing antibodies . The ST2 murine stromal cell line is frequently used for this purpose due to its responsiveness to IL-17 stimulation .

The experimental procedure typically includes:

• Culturing responsive cells (e.g., ST2 cells) in appropriate medium

• Pre-incubating IL-17 cytokines (IL-17A, IL-17F, or IL-17AF) with test antibodies

• Adding the antibody-cytokine mixture to cells, often with a sub-optimal dose of TNF-α to observe synergistic signaling

• Measuring downstream inflammatory mediators (e.g., IL-6) in conditioned supernatants after 24 hours

• Comparing the inhibitory capacity of different antibodies at various concentrations

This approach allows quantitative assessment of antibody potency and specificity against different IL-17 family members. Surface plasmon resonance (SPR) is often used as a complementary technique to determine binding kinetics and affinity constants .

How can researchers differentiate between the effects of individual IL-17 family members in complex biological systems?

Differentiating between the effects of individual IL-17 family members in complex biological systems requires a multi-faceted approach:

• Genetic models: Utilizing knockout mice deficient in specific IL-17 family members (e.g., IL-17A−/−, IL-17F−/−) or their receptors (IL-17RA−/−, IL-17RC−/−) allows researchers to study the consequences of complete absence of specific cytokines . These models provide fundamental insights but have limitations due to potential developmental compensation.

• Selective antibody neutralization: Administering antibodies with validated specificity against individual IL-17 family members or combinations thereof allows temporal control over cytokine neutralization . This approach more closely mimics therapeutic intervention and avoids developmental compensation issues.

• Combinatorial approaches: Comparing the phenotypes observed in genetic knockouts with those resulting from selective antibody neutralization can reveal complementary insights about the roles of individual cytokines.

• Expression analysis: Measuring the relative expression levels of different IL-17 family members in the biological system under study provides context for interpreting neutralization experiments. For instance, in OPC, IL-17A levels were found to be higher than IL-17AF levels, helping explain the stronger effect of anti-IL-17A antibodies compared to anti-IL-17AF antibodies .

• Downstream signaling analysis: Examining the activation of specific signaling pathways (e.g., through the adaptor Act1) following stimulation with different IL-17 family members can reveal unique signaling signatures .

What methodological considerations are important when designing antibodies with enhanced specificity profiles?

Designing antibodies with enhanced specificity profiles, particularly for distinguishing between similar cytokines like IL-17A and IL-17F, involves several important methodological considerations:

• Structural analysis: Understanding the three-dimensional structures of target antigens and their interfaces with existing antibodies provides a foundation for rational design . Crystal structures of antigen-antibody complexes are particularly valuable for identifying key interaction residues.

• Phage display optimization: Selection conditions in phage display experiments significantly impact the specificity profiles of resulting antibodies. Parameters such as target concentration, washing stringency, and competitive elution strategies can be tuned to enrich for antibodies with desired specificity characteristics .

• Computational modeling: Advanced computational methods can identify potential mutations that enhance binding to desired targets while reducing interaction with unwanted targets. This approach was successfully employed in the development of bimekizumab through identification of five mutations in the light chain variable region .

• Validation in multiple assay systems: Candidate antibodies should be evaluated using complementary techniques including:

  • Surface plasmon resonance for binding kinetics

  • Cell-based functional assays

  • Epitope mapping to confirm the binding site

  • Cross-reactivity panels to assess potential off-target binding

• Iterative optimization: The development process typically involves multiple rounds of design, testing, and refinement to achieve the desired specificity profile .

How do IL-17A-specific antibodies compare to dual IL-17A/F inhibitors in clinical research settings?

In clinical research settings, IL-17A-specific antibodies (like secukinumab and ixekizumab) have been compared with dual IL-17A/F inhibitors (like bimekizumab) to understand their relative efficacy and safety profiles:

What experimental evidence supports the rationale for dual inhibition of IL-17A and IL-17F?

Several lines of experimental evidence support the rationale for dual inhibition of IL-17A and IL-17F:

• Structural and functional similarities: IL-17A and IL-17F share structural homology and signal through the same receptor complex (IL-17RA/IL-17RC), suggesting overlapping biological functions .

• Cooperative effects in infection models: Studies in mouse models of oropharyngeal candidiasis have shown a cooperative effect when blocking IL-17A, IL-17AF, and IL-17F together, suggesting complementary roles in host defense .

• Expression in disease tissues: Both IL-17A and IL-17F have been shown to be functionally dysregulated in certain human immune-mediated inflammatory diseases such as psoriasis, psoriatic arthritis, and axial spondyloarthritis .

• In vitro functional assays: Dual inhibition of IL-17A and IL-17F in cellular assays demonstrates more complete blockade of inflammatory signaling compared to selective IL-17A inhibition .

• Comparative antibody studies: Bimekizumab, which neutralizes both IL-17A and IL-17F, showed promising results in Phase 2 clinical studies across multiple inflammatory conditions, supporting the targeted approach of dual neutralization .

This evidence collectively suggests that dual inhibition of IL-17A and IL-17F may provide a greater depth of clinical response in IL-17-mediated diseases than IL-17A inhibition alone .

How might computational approaches further enhance antibody design for complex cytokine networks?

Future computational approaches for antibody design targeting complex cytokine networks may advance in several directions:

• Integration of multiple data types: Combining high-throughput sequencing data from phage display experiments with structural information, molecular dynamics simulations, and functional assay results could provide a more comprehensive foundation for computational design .

• Machine learning advancements: Deep learning approaches trained on extensive antibody-antigen interaction datasets may better predict the effects of specific mutations on binding properties, allowing more precise customization of specificity profiles .

• Binding mode classification: Further refinement of computational methods to identify and disentangle different binding modes associated with particular ligands could enhance the ability to design antibodies that selectively recognize specific members of closely related protein families .

• Optimization of multi-parameter objectives: Developing algorithms that simultaneously optimize multiple parameters (affinity, specificity, stability, manufacturability) would address the real-world constraints of antibody development .

• In silico screening of larger sequence spaces: Computational approaches allow exploration of antibody sequence possibilities far beyond what can be covered in experimental libraries, potentially uncovering novel solutions to challenging specificity engineering problems .

These computational advances would complement experimental approaches, potentially accelerating the development of next-generation antibodies with precisely engineered specificity profiles for complex cytokine networks.

What are the methodological considerations for studying IL-17 antibody effects in combination with other immunomodulatory approaches?

Studying IL-17 antibody effects in combination with other immunomodulatory approaches requires careful methodological consideration:

• Sequential vs. simultaneous blockade: Determining whether to administer anti-IL-17 antibodies simultaneously with other immunomodulators or in a sequential manner can significantly impact results. Each approach models different clinical scenarios and may reveal distinct biological interactions.

• Dosing optimization: Establishing appropriate dosing regimens that account for potential synergistic or antagonistic effects between combined agents is crucial. Sub-optimal doses of individual agents may reveal synergies not apparent at maximally effective doses.

• Temporal considerations: The timing of interventions relative to disease induction or progression in experimental models can dramatically influence outcomes, particularly when targeting cytokines involved in different phases of the immune response.

• Comprehensive readout systems: Employing multiple complementary readouts (e.g., histological assessment, cytokine profiling, transcriptomics, immune cell phenotyping) provides a more complete picture of how combination approaches affect complex immune networks.

• Genetic background considerations: The effects of immunomodulatory combinations may vary substantially across different genetic backgrounds in animal models, necessitating testing in multiple strains to ensure robustness of findings.

• Translational relevance: Designing combination studies that model clinical scenarios as closely as possible enhances the translational value of preclinical research, particularly when informed by observations from clinical studies.